Top 10 Multiple Sclerosis startups in USA

Oct 12, 2024 | By Jason Kwon

1
Funding: $535.8M
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, multiple sclerosis (MS).
2
Funding: $526.3M
Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases.
3
Funding: $409M
Pear Therapeutics develops digital therapies to address a broad range of severe conditions including addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and sleep. PEAR’s eFormulationTM platform combines pharmaceutical preparations with user-friendly, customizable, and scientifically validated software applications. PEAR’s patented approach provides better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payors. Pear Therapeutics filed for bankruptcy
4
Funding: $183M
Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class that advances programs in multiple sclerosis and psoriasis
5
Funding: $135.5M
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
6
Funding: $91M
Octave is a biotechnology company that uses precision medicine and scientific insights to treat patients with multiple sclerosis.
7
Funding: $70M
Landos Biopharma is a developer of an oral first-in-class therapeutics designed to target autoimmune diseases.
8
Funding: $10.5M
AxoSim's Nerve-on-a-Chip platform facilitates prediction of both clinical neurotoxicity and efficacy in human neurodegenerative disease models earlier in the drug development pipeline.
9

Oscine Therapeutics is harnessing the power of stem cell science to revolutionize treatment of CNS diseases
10

BeCare Link connects patients to physicians and researchers, through the use of a user-friendly mobile app, to provide unprecedented levels of insight about MS and other neurodegenerative diseases.
Editor: Jason Kwon
Jason Kwon is a senior editor for MedicalStartups. He has previously covered the pharmaceutical and medical research industries for FDAnews and worked as a head of marketing for medical startup Sonic Therapeutics. Before that, he co-founded a startup consulting business for emerging entrepreneurial hubs in Asia. Jason graduated from St. Bonaventure University’s journalism school. In his free time, Jason enjoys yoga, watching movie trailers, traveling to places where he can't get cell service. You can contact Jason at jaskwon(at)medicalstartups(dot)com